DOI:

10.37988/1811-153X_2024_1_76

Mucoromycosis of the maxillofacial region: A review

Downloads

Authors

  • E.V. Riabykh 1, assistant at the Pediatric dentistry and dental diseases prophylaxis Department
    ORCID: 0000-0003-1855-0329
  • D.O. Riabykh 1, assistant at the Prosthodontics Department
    ORCID: 0009-0006-7914-9474
  • A.A. Nesterov 1, PhD in Medical Sciences, associate professor of the Maxillofacial surgery Department
    ORCID: 0000-0002-9042-4995
  • A.V. Ostanin 1, PhD in Medical Sciences, associate professor of the Maxillofacial surgery Department
    ORCID: 0000-0001-9546-3902
  • R.N. Nurmukhamedov 1, 5th year student at the Dental Faculty
    ORCID: 0009-0001-5372-4518
  • 1 Astrakhan State Medical University, 414000, Astrakhan, Russia

Abstract

This review article examines the relevance of the problem, etiological factors, classification, diagnosis, differential diagnosis, and principles of treatment of mucormycosis. The purpose of the study — to summarize the data on mucormycosis, to identify the most rational methods of diagnosis and treatment of this disease. Previously, mucormycosis was better known in tropical countries, in particular, in India. However, with the onset of the COVID-19 pandemic, an increase in the number of immunosuppressive conditions (against the background of diabetes mellitis, HIV infection, oncological pathology, etc.), the disease is increasingly common in Russia and European countries. Due to the low awareness of the medical community about the forms of mucormycosis, methods of diagnosis and treatment, the mortality rate is quite high. Mucormycosis manifests itself in 5 forms: rhino-orbital-cerebral, pulmonary, disseminated, cutaneous, gastrointestinal, and has a wide range of symptoms. The most rational diagnostic methods are direct microscopy of the fungus with fluorescent examination of biological samples, histological examination of tissues, computer and multispiral tomography, endoscopy of the nasal cavity, ultrasound examination. With the correct diagnosis, conservative and surgical treatment is carried out. Liposomal amphotericin B, posaconazole or izavuconazole showed high efficacy.

Key words:

mucormycosis, mucormycosis of the maxillofacial region, fungal infections, COVID-19

For Citation

[1]
Riabykh E.V., Riabykh D.O., Nesterov A.A., Ostanin A.V., Nurmukhamedov R.N. Mucoromycosis of the maxillofacial region: A review. Clinical Dentistry (Russia).  2024; 27 (1): 76—83. DOI: 10.37988/1811-153X_2024_1_76

References

  1. Lipnitsky A.V., Polovets N.V., Surkova R.S., Murugova A.A., Toporkov A.V., Victorov D.V. COVID-19 and mucormycosis. Immunopathology, Allergology, Infectology. 2021; 4: 65—71 (In Russian). eLIBRARY ID: 48291319
  2. Divakar P.K. Fungal taxa responsible for mucormycosis/”Black Fungus” among COVID-19 patients in India. J Fungi (Basel). 2021; 7 (8): 641. PMID: 34436180
  3. Malhotra H.S., Gupta P., Mehrotra D., Dandu H., Kohli N., Verma V., Kaur A., Kumar N., Prabhu V., Singh M.K., Jaiswal R., Mishra B., Ojha B.K., Bhardwaj N.D., Atam V., Puri B. COVID-19 associated mucormycosis: Staging and management recommendations (Report of a multi-disciplinary expert committee). J Oral Biol Craniofac Res. 2021; 11 (4): 569—580. PMID: 34395187
  4. Rao V.U.S., Arakeri G., Madikeri G., Shah A., Oeppen R.S., Brennan P.A. COVID-19 associated mucormycosis (CAM) in India: a formidable challenge. Br J Oral Maxillofac Surg. 2021; 59 (9): 1095—1098. PMID: 34507870
  5. Aiyar Y., Chandru V., Chatterjee M., Desai S., Fernandez A., Gupta A., Kang G., Khanna T., Mazumdar-Shaw K., Mor N., Mukherji A., Muttreja P., Narayan T., Patwardhan B., Rao K.S., Sharma S., Shetty D., Subramanian S.V., Varkey L.E.C., Venkateswaran S., Patel V. India's resurgence of COVID-19: urgent actions needed. Lancet. 2021; 397 (10291): 2232—2234. PMID: 34048696
  6. Park B.J., Pappas P.G., Wannemuehler K.A., Alexander B.D., Anaissie E.J., Andes D.R., Baddley J.W., Brown J.M., Brumble L.M., Freifeld A.G., Hadley S., Herwaldt L., Ito J.I., Kauffman C.A., Lyon G.M., Marr K.A., Morrison V.A., Papanicolaou G., Patterson T.F., Perl T.M., Schuster M.G., Walker R., Wingard J.R., Walsh T.J., Kontoyiannis D.P. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001—2006. Emerg Infect Dis. 2011; 17 (10): 1855—64. PMID: 22000355
  7. Jeong W., Keighley C., Wolfe R., Lee W.L., Slavin M.A., Kong D.C.M., Chen S.C. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019; 25 (1): 26—34. PMID: 30036666
  8. Kontoyiannis D.P., Yang H., Song J., Kelkar S.S., Yang X., Azie N., Harrington R., Fan A., Lee E., Spalding J.R. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis. 2016; 16 (1): 730. PMID: 27905900
  9. Chakrabarti A., Singh R. Mucormycosis in India: unique features. Mycoses. 2014; 57 Suppl 3: 85—90. PMID: 25187095
  10. Bitar D., Van Cauteren D., Lanternier F., Dannaoui E., Che D., Dromer F., Desenclos J.C., Lortholary O. Increasing incidence of zygomycosis (mucormycosis), France, 1997—2006. Emerg Infect Dis. 2009; 15 (9): 1395—401. PMID: 19788806
  11. Ruhnke M., Groll A.H., Mayser P., Ullmann A.J., Mendling W., Hof H., Denning D.W., University of Manchester in association with the LIFE program Estimated burden of fungal infections in Germany. Mycoses. 2015; 58 Suppl 5: 22—8. PMID: 26449503
  12. Burova S.A., Taganov A.V., Kashtanova A.A., Gorbacheva Yu.V. Mucormycosis is a dangerous and real fungal superinfection during the COVID-19 pandemic. Advances in Medical Mycology. 2022; 23: 51—54 (In Russian). eLIBRARY ID: 49533102
  13. Skiada A., Pagano L., Groll A., Zimmerli S., Dupont B., Lagrou K., Lass-Florl C., Bouza E., Klimko N., Gaustad P., Richardson M., Hamal P., Akova M., Meis J.F., Rodriguez-Tudela J.L., Roilides E., Mitrousia-Ziouva A., Petrikkos G., European Confederation of Medical Mycology Working Group on Zygomycosis. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011; 17 (12): 1859—67. PMID: 21199154
  14. Khostelidi S.N., Shadrivova O.V., Borzova U.V., Desyatik E.A., Nicolaeva N.G., Bogomolova T.S., Avdeenko U.L., Volkova A.G., Popova M.O., Zubarovskaya L.S., Kolbin A.S., Medvedeva N.V., Podoltseva E.I., Klimovich A.V., Lebedeva M.S., Semelev V.N., Zuzgin I.S., Chudinovskih U.A., Uspenskaya O.S., Saturnov A.V., Klimko N.N. Clinical and laboratory features of mucormycosis in adults. Problems in Medical Mycology . 2020; 2: 22—28 (In Russian). eLIBRARY ID: 44027907
  15. Reid G., Lynch J.P. 3rd, Fishbein M.C., Clark N.M. Mucormycosis. Semin Respir Crit Care Med. 2020; 41 (1): 99—114. PMID: 32000287
  16. Neblett Fanfair R., Benedict K., Bos J., Bennett S.D., Lo Y.C., Adebanjo T., Etienne K., Deak E., Derado G., Shieh W.J., Drew C., Zaki S., Sugerman D., Gade L., Thompson E.H., Sutton D.A., Engelthaler D.M., Schupp J.M., Brandt M.E., Harris J.R., Lockhart S.R., Turabelidze G., Park B.J. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med. 2012; 367 (23): 2214—25. PMID: 23215557
  17. Warkentien T., Rodriguez C., Lloyd B., Wells J., Weintrob A., Dunne J.R., Ganesan A., Li P., Bradley W., Gaskins L.J., Seillier-Moiseiwitsch F., Murray C.K., Millar E.V., Keenan B., Paolino K., Fleming M., Hospenthal D.R., Wortmann G.W., Landrum M.L., Kortepeter M.G., Tribble D.R., Infectious Disease Clinical Research Program Trauma Infectious Disease Outcomes Study Group. Invasive mold infections following combat-related injuries. Clin Infect Dis. 2012; 55 (11): 1441—9. PMID: 23042971
  18. Hartnett K.P., Jackson B.R., Perkins K.M., Glowicz J., Kerins J.L., Black S.R., Lockhart S.R., Christensen B.E., Beer K.D. A Guide to investigating suspected outbreaks of mucormycosis in healthcare. J Fungi (Basel). 2019; 5 (3): 69. PMID: 31344775
  19. Lanternier F., Dannaoui E., Morizot G., Elie C., Garcia-Hermoso D., Huerre M., Bitar D., Dromer F., Lortholary O., French Mycosis Study Group. A global analysis of mucormycosis in France: the RetroZygo Study (2005—2007). Clin Infect Dis. 2012; 54 Suppl 1: S35—43. PMID: 22247443
  20. Bhattacharyya A., Sarma P., Sharma D.J., Das K.K., Kaur H., Prajapat M., Kumar S., Bansal S., Prakash A., Avti P., Thota P., Reddy D.H., Gautam B.S., Medhi B. Rhino-orbital-cerebral-mucormycosis in COVID-19: A systematic review. Indian J Pharmacol. 2021; 53 (4): 317—327. PMID: 34414911
  21. Zelter P.M., Surovcev E.N., Kolsanov A.V., Zeleva O.V., Sidorov E.A., Ivanova O.V., Pyshkina Yu.S., Tsoy A.V. Radiology of rhinoorbitocerebral mycormycosis in patients after COVID-19. Russian Electronic Journal of Radiology. 2022; 4: 5—21 (In Russian). eLIBRARY ID: 50056487
  22. Kury`sheva N.I., Kim V.Yu., Plieva X.M., Kim V.E., Nekrasova E.Yu. Mucormycosis and its ocular manifestations. Moscow: Burnasyan Federal Medical Biophysical Center, 2022. 22 p. (In Russian). eLIBRARY ID: 49499190
  23. Baranova I.B., Yaremenko A.I., Zubareva A.A., Karpischenko S.A., Popova M.O., Kurus A.A., Portnov G.V., Pinegina O.N., Lukina O.V., Malyarevskaya M.V., Kalakuckiy I.N., Ilyukhina M.O., Klimko N.N. Mucormycosis of the bones of the facial skull, nasal cavity and paranasal sinuses in patients with COVID-19. Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 4: 347—358 (In Russian). eLIBRARY ID: 48163909
  24. Revannavar S.M., Supriya P.S., Samaga L., Vineeth V.K. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? — BMJ Case Rep. 2021; 14 (4): e241663. PMID: 33906877
  25. Garg D., Muthu V., Sehgal I.S., Ramachandran R., Kaur H., Bhalla A., Puri G.D., Chakrabarti A., Agarwal R. Coronavirus disease (Covid-19) associated mucormycosis (CAM): Case report and systematic review of literature. Mycopathologia. 2021; 186 (2): 289—298. PMID: 33544266
  26. Sharma S., Grover M., Bhargava S., Samdani S., Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. 2021; 135 (5): 442—447. PMID: 33827722
  27. Donnelly J.P., Chen S.C., Kauffman C.A., Steinbach W.J., Baddley J.W., Verweij P.E., Clancy C.J., Wingard J.R., Lockhart S.R., Groll A.H., Sorrell T.C., Bassetti M., Akan H., Alexander B.D., Andes D., Azoulay E., Bialek R., Bradsher R.W., Bretagne S., Calandra T., Caliendo A.M., Castagnola E., Cruciani M., Cuenca-Estrella M., Decker C.F., Desai S.R., Fisher B., Harrison T., Heussel C.P., Jensen H.E., Kibbler C.C., Kontoyiannis D.P., Kullberg B.J., Lagrou K., Lamoth F., Lehrnbecher T., Loeffler J., Lortholary O., Maertens J., Marchetti O., Marr K.A., Masur H., Meis J.F., Morrisey C.O., Nucci M., Ostrosky-Zeichner L., Pagano L., Patterson T.F., Perfect J.R., Racil Z., Roilides E., Ruhnke M., Prokop C.S., Shoham S., Slavin M.A., Stevens D.A., Thompson G.R., Vazquez J.A., Viscoli C., Walsh T.J., Warris A., Wheat L.J., White P.L., Zaoutis T.E., Pappas P.G. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. . — Clin Infect Dis. — 2020; 71 (6): 1367—1376. PMID: 31802125
  28. Jung J., Kim M.Y., Lee H.J., Park Y.S., Lee S.O., Choi S.H., Kim Y.S., Woo J.H., Kim S.H. Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. Clin Microbiol Infect. 2015; 21 (7): 684.e11—8. PMID: 25882362
  29. Hammer M.M., Madan R., Hatabu H. Pulmonary mucormycosis: Radiologic features at presentation and over time. AJR Am J Roentgenol. 2018; 210 (4): 742—747. PMID: 29470162
  30. Miceli M.H., Chandrasekar P. Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients. Infect Drug Resist. 2012; 5: 9—16. PMID: 22294858
  31. Espinel-Ingroff A., Chakrabarti A., Chowdhary A., Cordoba S., Dannaoui E., Dufresne P., Fothergill A., Ghannoum M., Gonzalez G.M., Guarro J., Kidd S., Lass-Flörl C., Meis J.F., Pelaez T., Tortorano A.M., Turnidge J. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. Antimicrob Agents Chemother. 2015; 59 (3): 1745—50. PMID: 25583714
  32. Biswas D., Kotwal A., Kakati B., Ahmad S. Amphotericin B resistant apophysomyces elegans causing rhino-oculo-cerebral mucormycosis in an immunocompetent host. J Clin Diagn Res. 2015; 9 (8): DD01—2. PMID: 26435947
  33. Steinbrink J.M., Miceli M.H. Mucormycosis. Infect Dis Clin North Am. 2021; 35 (2): 435—452. PMID: 34016285
  34. Skiada A., Lass-Floerl C., Klimko N., Ibrahim A., Roilides E., Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018; 56 (suppl_1): 93—101. PMID: 29538730
  35. Roilides E., Antachopoulos C., Simitsopoulou M. Pathogenesis and host defence against Mucorales: the role of cytokines and interaction with antifungal drugs. Mycoses. 2014; 57 Suppl 3: 40—7. PMID: 25175306
  36. Walsh T.J., Gamaletsou M.N., McGinnis M.R., Hayden R.T., Kontoyiannis D.P. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012; 54 Suppl 1: S55—60. PMID: 22247446
  37. Gebremariam T., Lin L., Liu M., Kontoyiannis D.P., French S., Edwards J.E. Jr, Filler S.G., Ibrahim A.S. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. J Clin Invest. 2016; 126 (6): 2280—94. PMID: 27159390
  38. Kim J.H., Benefield R.J., Ditolla K. Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection. Mycoses. 2016; 59 (11): 726—733. PMID: 27392814
  39. Ma J., Jia R., Li J., Liu Y., Li Y., Lin P., Zhang M., Li M. Retrospective clinical study of eighty-one cases of intracranial mucormycosis. J Glob Infect Dis. 2015; 7 (4): 143—50. PMID: 26752868
  40. Bekaeva U.B., Galkina O.P., Vydashenko A.V. Oral candidiasis combined with COVID-19 (literature review). Clinical Dentistry (Russia). 2022; 3: 104—111 (In Russian). eLIBRARY ID: 49514210
  41. Vaughan C., Bartolo A., Vallabh N., Leong S.C. A meta-analysis of survival factors in rhino-orbital-cerebral mucormycosis-has anything changed in the past 20 years? — Clin Otolaryngol. 2018; 43 (6): 1454—1464. PMID: 29947167

Downloads

Received

September 17, 2023

Accepted

February 4, 2024

Published on

March 21, 2024